Prostate Cancer

Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer

San Francisco, CA ( -- Myovant Sciences, a healthcare company focused on developing innovative treatments for women's health and prostate cancer, announced that the Phase 3 HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint and all six key secondary endpoints in men with advanced prostate cancer. These results support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the second quarter of 2020 and future regulatory submissions in Europe and Japan.

Study Finds Multidisciplinary Clinics Increase Treatment Options, Adherence for Prostate Cancer

San Francisco, CA ( -- Newly diagnosed prostate cancer patients have multiple standard-of-care treatment options available, but many are not fully informed of their choices. A study led by researchers at The University of Texas MD Anderson Cancer Center found men who seek treatment at a multidisciplinary (MultiD) prostate cancer clinic are more likely to be advised about treatment choices and to receive care that complies with evidence-based treatment guidelines. African American men who visited the MultiD clinic also were more likely to receive definitive, or curative, therapy, compared with national trends.

Contemporary Prostate Cancer Treatment Choices in Multidisciplinary Clinics Referenced to National Trends

Background: The purpose of this study was to assess treatment choices among men with prostate cancer who presented at The University of Texas MD Anderson Cancer Center multidisciplinary (MultiD) clinic compared with nationwide trends.

Combining prostate cancer radiotherapy with therapies targeting the androgen receptor axis.

Prostate cancer (pca) is the most common non-dermatologic cancer and the 3rd leading cause of male cancer mortality in Canada. In patients with high-risk localized or recurrent pca, management typically includes the combination of long-term androgen deprivation therapy (adt) and radiotherapy (rt).

Development and external validation of a nomogram to predict lymph node invasion after robot assisted radical prostatectomy.

Prediction of lymph node invasion (LNI) after radical prostatectomy has been rarely assessed in robotically assisted laparoscopic radical prostatectomy (RALP) series. We aimed to develop and externally validate a pretreatment nomogram for the prediction of LNI following RALP in patients with high- and intermediate-risk prostate cancer.

Photodynamic Therapy is an Effective Adjuvant Therapy for Image-Guided Surgery in Prostate Cancer.

Local and metastatic relapse of prostate cancer often occur following attempted curative resection of the primary tumor and up to 66% of local recurrences are associated with positive margins. Therefore, technologies that can improve the visualization of tumor margins and adjuvant therapies to ablate remaining tumor tissues are needed during surgical resection of prostate adenocarcinoma.

Head-to-head comparison of prostate MRI using an endorectal coil versus a non-endorectal coil: meta-analysis of diagnostic performance in staging T3 prostate cancer.

To compare the diagnostic performance of prostate magnetic resonance imaging (MRI) with an endorectal coil (ERC) to performance without an ERC using either body-array (BAC) or pelvic phased-array coil (PAC) in staging T3 prostate cancer.

Ten-Year Treatment Outcomes of Radical Prostatectomy vs External Beam Radiation Therapy vs Brachytherapy for 1,503 Patients with Intermediate Risk Prostate Cancer.

To compare 10-year oncologic treatment outcomes of radical prostatectomy (RP) vs external beam radiation therapy (EBRT) vs brachytherapy (BT) for patients with intermediate risk prostate cancer (IRPC).

Rename Breast-Cancer Syndrome to Help Save Lives

People of all sexes can have risk genes that are often assumed to affect only women. A new name could aid cancer prevention and treatment, argues Colin C. Pritchard. I recently had a conversation with my parents about genetic testing for cancer risk. “You mean men also have the BRCA genes?” asked my dad. “I thought those were the breast-cancer genes,” chimed in my mom.

Stereotactic body radiation therapy to the prostate bed: results of a phase I dose escalation trial.

The primary objectives of this study were to evaluate toxicity of escalating doses of prostate bed SBRT and provide dose recommendations for phase II study.

Patients with organ-confined, node-negative prostate cancer who had biochemical failure (Prostate-specific antigen [PSA] less than 2.

Diagnostic properties of total and free prostate-specific antigen to predict overall and clinically significant prostate cancer among men with low testosterone and prior negative biopsy.

To evaluate whether total serum PSA, free-PSA ratio and PSA density have similar diagnostic properties for detecting prostate cancer (PCa) and clinically-significant (cs) PCa in men with normal testosterone compared to men with low testosterone with a prior negative biopsy.

The added value of diffusion-weighted images and dynamic contrast-enhancement in multi-parametric MRI for the detection of clinically significant prostate cancer in the PICTURE trial.

To determine the additional diagnostic value of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) imaging in men requiring a repeat biopsy within the PICTURE study.

PICTURE was a paired-cohort confirmatory study in which 249 men who required further risk stratification following a previous non-MRI guided TRUS biopsy underwent a 3-Tesla mpMRI consisting of T2W, DWI and DCE followed by transperineal template prostate mapping (TPM) biopsy.

Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.

The importance of local failure (LF) after treatment of high-grade prostate cancer (PCa) with definitive radiotherapy (RT) remains unknown.

To evaluate the clinical implications of LF after definitive RT.

Helping Men Find Their Way: Improving Prostate Cancer Clinic Attendance via Patient Navigation.

Navigation programs aim to help patients overcome barriers to cancer diagnosis and treatment. Missed clinic appointments have undesirable effects on the patient, health system, and society, and treatment delays have been shown to result in inferior surgical cure rates for men with prostate cancer (CaP).

Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy.

Adjuvant (ART) and salvage radiotherapy (SRT) are two common concepts to enhance biochemical relapse free survival (BCRFS) in patients with prostate cancer (PC). We analyzed differences in outcome between ART and SRT in patients with steep decline of PSA-levels after surgery to compare outcome.

Exploring health behaviors, quality of life, and support needs in African-American prostate cancer survivors: a pilot study to support future interventions.

Prostate cancer incidence and mortality rates are highest among African-American men. Comorbidity burden and quality of life (QOL) challenges are also high. Many factors drive these differences; health behaviors are important modifiable contributors.

Corticosteroid switch after progression on abiraterone acetate plus prednisone.

Abiraterone acetate plus prednisone is approved in metastatic castration-resistant prostate cancer. There is some evidence in favour of the steroid switch from prednisone to dexamethasone in patients who progressed whilst on abiraterone acetate plus prednisone or prednisolone.

Magnetic resonance image-guided focal laser ablation in clinically localized prostate cancer: safety and efficacy.

To evaluate the safety and efficacy of focal laser ablation (FLA) in low-intermediate risk prostate cancer.

Inclusion criteria were men aged 50-75 years, prostate-specific antigen (PSA) ≤15 ng/mL, clinical stage T1c-T2a, one or two lesions (PI-RADS ≥3) on magnetic resonance imaging (MRI), and Gleason score 6 (>3 mm) or Gleason 7 on targeted biopsy.

Novel agents for metastatic hormone-sensitive prostate cancer - A practice guide for urologists.

The last five years has witnessed a remarkable evolution in the management of metastatic hormone-sensitive prostate cancer (mHSPC), with multiple agents demonstrating profound benefit in combination with initial androgen deprivation therapy (ADT).

Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition - Beyond the Abstract

The success of multiparametric magnetic resonance imaging (mpMRI) for reliably detecting and localizing clinically significant (cs) prostate cancer (PCa) is highly dependent on image quality. However, due to the variability of available MRI equipment including software levels and prostate MRI technologists’ (MRI radiographers’) experience, it can be challenging to consistently achieve good-quality images for detection, localization, staging, and follow-up of PCa. The first step to improve quality and reduce variability is to implement optimized acquisition protocols.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.